OncoTherics Limited was formed in 2009, to exploit a novel anti-cancer drug technology, targeting hypoxia resistant cancer cells.

The company's unidirectional Hypoxia Activated Prodrugs (uHAPs) are uniquely able to reach areas of the tumour that are untreatable by conventional chemotherapy and radiotherapy.

OncoTherics was formed by BioStatus Limited, who have funded all of the company's research and development to date. More details about BioStatus can be found at biostatus.com OncoTherics Limited is a company registered in England and Wales, reg no: 06940617

OncoTherics Poland Sp. Zo.o. was formed in 2018 as a wholly owned Subsidiary of OncoTherics Limited to progress the commercialisation of the OncoTherics technology.

OncoTherics Poland is a company incorporated and registered in Poland with registered office at ul. Bobrzynskiego 14, 30-348 Krakow, Poland.

For further information please contact: enquiry@oncotherics.com